Neuroscience
At J&J Innovative Medicine, our history is tied to neuroscience. We have a legacy of more than 50 years developing treatments for mental illnesses. The first breakthrough treatment2 was developed by Dr. Paul Janssen to treat schizophrenia. Today, we are more committed than ever to leading the charge to discover novel treatments for our patients so that they can lead normal and healthy lives.
Our portfolio in neuroscience treats a diverse range of neuropsychiatric conditions, from schizophrenia to depression. While we have made much progress in neuroscience, we are determined to continue to raise the bar to make mental healthcare a priority worldwide.

Schizophrenia
You are now leaving the website ofJ&J Innovative Medicine (Hong Kong)
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.

Attention Deficit Hyperactivity Disorder
You are now leaving the website ofJ&J Innovative Medicine (Hong Kong)
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
You are now leaving the website ofJ&J Innovative Medicine (Hong Kong)
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.

Depression
You are now leaving the website ofJ&J Innovative Medicine (Hong Kong)
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
References
1 World Health Organization. The World Health Report 2001: Mental Disorders affect one in four people. September 28, 2001. Accessed November 26, 2020. https://web.archive.org/web/20201116211340/https://www.who.int/news/item/28-09-2001-the-world-health-report-2001-mental-disorders-affect-one-in-four-people.
2 Janssen Asia Pacific. Neuroscience. Updated October 20, 2020. Accessed November 26, 2020. https://web.archive.org/web/20201130123034/https://www.janssen.com/apac/health-information/neuroscience.
3 The Government of Hong Kong Special Administrative Region. Community support services for patients with mental illness. December 14, 2016. Accessed November 26, 2020. https://web.archive.org/web/20190901025801/https:/www.info.gov.hk/gia/general/201612/14/P2016121400645.htm.
4 Acosta JA, et al. Medication adherence in schizophrenia. World J Psychiatry 2012; 2(5):74-82.
5 Sayal K, et al. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry 2018; 5(2):175-186.
6 Liu A, et al. The prevalence of attention deficit/hyperactivity disorder among Chinese children and adolescents. Scientific Reports 2018; 11169:1-15.
7 Ni MY, et al. Depression and post-traumatic stress during major social unrest in Hong Kong: a 10-year prospective cohort study. Lancet 2020; 395(10):273-284.